Revenue Recognition (Details) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2023 USD ($) item $ / shares	Sep. 30, 2022 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Aug. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)
Deferred revenue, Long-term	$ 21,033		$ 21,033		$ 20,001
Increased (decreased) revenues	2,200	$ 5,900	(3,700)	$ 16,500
(Increased) decreased net loss	$ 2,200	$ 5,900	$ (3,700)	$ 16,500
(Increased) decreased net loss per share | $ / shares	$ 0.02	$ 0.06	$ (0.03)	$ 0.17
Other assets	$ 16,208		$ 16,208		18,330
Deferred revenue	36,045	$ 28,337	36,045	$ 28,337	30,778	$ 28,722
Deferred revenue, current portion	15,012		15,012		10,777
Total revenues	268,306	210,637	771,466	602,970
Deferred revenue, long-term portion	21,033		21,033		20,001
Revenue recognized during the period that was included in deferred revenues at the beginning of the period			9,610	7,877
Product
Revenue recognized			7,700	4,000
Cost of revenues	146,962	115,436	$ 437,524	$ 326,862
Billing collection period (in months)			18 months
Increased (decreased) revenues	1,200	1,600
(Increased) decreased net loss	$ 1,200	$ 1,600
(Increased) decreased net loss per share | $ / shares	$ 0.01	$ 0.02	$ 0.07	$ 0.04
Total revenues	$ 265,218	$ 199,831	$ 761,271	$ 584,415
Licensing and other
Cost of revenues	349	1,076	1,060	2,102
Total revenues	3,088	$ 10,806	10,195	18,555
Genetic testing services
Deferred revenue, current portion	12,800		12,800
Revenue recognized during the period that was included in deferred revenues at the beginning of the period			$ 8,800
Laboratory distribution partners | Product | Minimum
Billing collection period (in months)			2 months
Laboratory distribution partners | Product | Maximum
Billing collection period (in months)			3 months
BGI Genomics
Revenue recognized			$ 44,000
Agreement term			10 years
Revenue, remaining performance obligation	6,000		$ 6,000
Deferred revenue, Long-term	19,300		19,300
Transaction price	50,000		50,000
Prepaid expenses and other current assets					4,000
Deferred revenue	19,300		19,300
Prepaid royalties	20,000		20,000
Deferred revenue, long-term portion	19,300		19,300
BGI Genomics | License and related development services
Revenue recognized			$ 100	7,300
Number of performance obligations | item			2
Revenue, remaining performance obligation	24,000		$ 24,000
BGI Genomics | Sequencing services
Other assets	6,000		6,000					$ 6,000
Equipment and services received	1,400
BGI Genomics | Sequencing products
Other assets								4,000
Prepaid expenses and other current assets	1,100		1,100
Equipment and services received			4,000
BGI Genomics | Sequencing products and services
Other assets	4,900		4,900					$ 10,000
BGI Genomics | Oncology assay interpretation services
Revenue recognized			1,100		$ 0
Revenue, remaining performance obligation	20,000		20,000
Deferred revenue	700		700
Foundation Medicine ("FMI")
Revenue recognized			$ 24,300
Agreement term			5 years
Automatic renewals, successive period thereafter			1 year
Revenue, remaining performance obligation	7,700		$ 7,700
Deferred revenue, Long-term	1,700		1,700
Transaction price							$ 32,000
Deferred revenue	3,900		3,900
Deferred revenue, current portion	2,200		2,200
Prepaid royalties	5,000		5,000
Deferred revenue, long-term portion	1,700		1,700
Foundation Medicine ("FMI") | Oncology assay interpretation services
Revenue recognized			300	100
Revenue, remaining performance obligation	5,000		5,000
Foundation Medicine ("FMI") | Oncology products
Revenue recognized			200	$ 2,900
Revenue, remaining performance obligation	$ 19,300		$ 19,300